sFas and sFas ligand and pediatric sepsis-induced multiple organ failure syndrome

Pediatric Research

Volumn 52, Issue 6, 2002, Pages 922-927

  Doughty, Lesley ^a   Clark, Robert S B ^b   Kaplan, Sandra S ^b   Sasser, Howell ^d   Carcillo, Joseph ^b,c  

^a RHODE ISLAND HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; INTERLEUKIN 10; INTERLEUKIN 6; NITRATE; NITRITE; AUTACOID; FAS ANTIGEN; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; CRITICAL ILLNESS; HUMAN; INFANT; INFLAMMATION; LIVER FAILURE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MULTIPLE ORGAN FAILURE; NEWBORN; PRIORITY JOURNAL; SCORING SYSTEM; SEPSIS; SURVIVAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VIRUS INFECTION; BIOLOGICAL MODEL; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; LIVER; PATHOPHYSIOLOGY; PRESCHOOL CHILD; SOLUBILITY;

ADOLESCENT; ADULT; ANTIGENS, CD95; APOPTOSIS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FAS LIGAND PROTEIN; HUMANS; INFANT; INFANT, NEWBORN; INFLAMMATION MEDIATORS; LIVER; MEMBRANE GLYCOPROTEINS; MODELS, IMMUNOLOGICAL; MULTIPLE ORGAN FAILURE; SEPSIS; SOLUBILITY;

EID: 85047686141     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/00006450-200212000-00018     Document Type: Article

References (42)

1. Lynch DH, Ramsdell F, Alderson MR 1995 Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 16:569-574
2. Green DR, Scott DW 1994 Activation-induced apoptosis in lymphocytes. Curr Opin Immunol 6:476-487
3. Mountz JD, Zhou T, Wu J, Wang W, Su X, Cheng J 1995 Regulation of apoptosis in immune cells. J Clin Immunol 15:1-16
4. Nagata S, Golstein P 1995 The Fas death factor. Science 267:1449-1456
5. Iwai K, Miyawaki T, Takizawa T, Konno A, Ohta K, Yachie A, Seki H, Taniguchi N 1994 Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 84:1201-1208
6. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ 1996 Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils. J Exp Med 184:429-440
7. Kiener PA, Davis PM, Starling GC, Mehlin C, Klebanoff SJ, Ledbetter JA, Liles WC 1997 Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med 185:1511-1516
8. Mangan DF, Welch GR, Wahl SM 1991 Lipopolysaccharide, tumor necrosis factor-, and IL-1 prevent programmed cell death (apoptosis) in human peripheral blood monocytes. J Immunol 146:1541-1546
9. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD 1994 Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762
10. Mountz JD, Zhou T, Bluethmann H, Wu J, Edwards 3rd CK 1994 Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice. Int Rev Immunol 1:321-342
11. Jimenez MF, Watson RW, Parodo J, Evans D, Foster D, Steinberg M, Rotstein OD, Marshall JC 1997 Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch Surg 132:1263-1267
12. Chitnis D, Dickerson C, Munster AM, Winchurch RA 1996 Inhibition of apoptosis in polymorphonuclear neutrophils from burn patients. J Leukoc Biol 59:835-839
13. Mountz JD, Baker TJ, Bocherding DR, Bluethmann H, Zhou T, Edwards 3rd CK 1995 Increased susceptibility of fas mutant MRL-lpr/lpr mice to staphylococcal enterotoxin B-induced septic shock. J Immunol 155:4829-4837
14. Doughty LA, Kaplan SS, Carcillo JA 1996 Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure. Crit Care Med 24:1137-1143
15. Doughty LA, Carcillo JA, Kaplan SS, Janosky J 1998 Plasma nitrite and nitrate concentrations and multiple organ failure in pediatric sepsis. Crit Care Med 26:157-162
16. Doughty L, Carcillo JA, Kaplan SS, Janosky J 1998 The compensatory antiinflammatory cytokine interleukin 10 response in pediatric sepsis-induced multiple organ failure. Chest 113:1625-1631
17. Endo S, Inada K, Takakuwa T, Kasai T, Yamada Y, Wakabayashi G, Niimi M, Suzuki T, Taniguchi S 1996 Nitrite/nitrate (NOx) and sFas antigen levels in patients with multiple organ failure. Res Commun Mol Pathol Pharmacol 92:253-256
18. Papathanassglou ED, Moynihan JA, Vermillion DL, McDermott MP, Ackerman MH 2000 Soluble Fas levels correlate with multiple organ dysfunction severity, survival, and nitrate levels, but not with cellular apoptotic markers in critically ill patients. Shock 14:107-112
19. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S 1997 Membrane Fas ligand kills peripheral blood T lymphocytes, and soluble fas ligand blocks the killing. J Exp Med 186:2045-2050
20. Tanaka M, Itai T, Adachi M, Nagata S 1998 Down regulation of fas ligand by shedding. Nat Med 4:31-36
21. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J 1998 Conversion of membrane bound fas (CD95) ligand to its soluble form is associated with down regulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187:1205-1213
22. Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S 1997 Lethal effects of recombinant human Fas ligand in mice treated with Propionibacterium acnes. J Immunol 158:2303-2309
23. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S 1993 Lethal effect of the anti-fas antibody in mice. Nature 364:806-809
24. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata 1996 Fas ligand in human serum. Nat Med 2:317-322
25. Ryo K, Kamogawa Y, Yamauchi K, Hayashi N 1996 Involvement of Fas and Fas ligand in case of fulminant hepatitis. Nippon Rinsho 54:1965-1969
26. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S 1997 Essential roles of the Fas ligand in the development of hepatitis. Nat Med 3:409-413
27. Bone RC, Fischer Jr CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA 1989 Sepsis syndrome: A valid clinical entity. Crit Care Med 17:389-393
28. Wilkinson JD, Pollack MM, Ruttiman UE, Glass NL, Yeh TS 1986 Outcome of pediatric patients with multiple organ system failure. Crit Care Med 14:271-274
29. Proulx F, Fayon M, Farrell CA, Lacroix J, Gauthier M 1996 Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest 109:1033-1037
30. 15N nitrate in biological fluids. Ann Biochem 126:131-138
31. Niitsu N, Sasaki K, Umeda M 1999 A high serum soluble fas/APO-1 is associated with a poor outcome of aggressive non-Hodgkins lymphoma. Leukemia 13:1434-1440
32. Munker R, Midis G, Owen-Schaub L, Andreff M 1996 Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes. Leukemia 10:1531-1533
33. Hori Y, Wada H, Mori Y, Shimura M, Hiyoyama K, Nakasaki T, Nishiik, Tamaki S, Nishikawa M, Deguchi K, Minami N, Shiku H 1999 Plasma sFas and sFas ligand levels in patients with thrombotic thrombocytopenic purpura and in those with disseminated intravascular coagulation. Am J Hematol 61:21-25
34. Al-Maini M, Mountz J, Al-Mohri H, El-Ageb E, Al-Riyami B, Svenson K, Zhou T, Richens E 2000 Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus. Lupus 9:132-139
35. Iio S, Hayashi N, Mita E, Ueda K, Mochizuki K, Hiramatsu N, Kanto T, Sasaki Y, Kasahara A, Hori M 1998 Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 29:517-523
36. Rodriguez I, Matsuura K, Ody C, Nagata S, Vassalli P 1996 Systemic injection of a tripeptide inhibits the intercellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J Exp Med 184:2067-2072
37. Rodriquez I, Matsuura K, Khatib K, Reed JC, Nagata S, Vassalli P 1996 A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J Exp Med 183:1031-1036
38. Lacronique V, Mignon A, Fabre M, Viollet B, Rouquet N, Molina T, Porteau A, Henrion A, Bluscary D, Varlet P, Joulin V, Kahn A 1996 Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat Med 2:80-86
39. Kosai K, Matsumoto K, Nagata S, Tsujimoto Y, Nakamura T 1998 Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun 244:683-690
40. Chung CS, Xu YX, Wang W, Chaudry IH, Ayala A 1998 Is Fas ligand or endotoxin responsible for mucosal lymphocyte apoptosis in sepsis? Arch Surg 133:1213-1220
41. Hattori K, Hirano T, Ushiyama C, Miyajima H, Yamakawa N, Ebata T, Wada Y, Ikeda S, Yoshino K, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K 1997 A metalloproteinase inhibitor prevents lethal acute graft versus host disease in mice. Blood 90:542-548
42. Hasegawa D, Kojima S, Tatsumi E, Hayakawa A, Kosaka Y, Nakamura H, Sako M, Osugi Y, Nagata S, Sano K 1998 Elevation of serum Fas ligand in patients with hemophagocytic syndrome and Diamond-Blackfan anemia. Blood 91:2793-2799